Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine - United States, May 3, 2023-April 14, 2024.
作者信息
Hause Anne M, Moro Pedro L, Baggs James, Zhang Bicheng, Marquez Paige, Melgar Michael, Britton Amadea, Stroud Erin, Myers Tanya R, Rakickas Jeffrey, Blanc Phillip G, Welsh Kerry, Broder Karen R, Su John R, Shay David K
出版信息
MMWR Morb Mortal Wkly Rep. 2024 May 30;73(21):489-494. doi: 10.15585/mmwr.mm7321a3.
Abstract
摘要
相似文献
1
Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine - United States, May 3, 2023-April 14, 2024.
MMWR Morb Mortal Wkly Rep. 2024 May 30;73(21):489-494. doi: 10.15585/mmwr.mm7321a3.
2
RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older.
JAMA. 2024 Oct 1;332(13):1105-1107. doi: 10.1001/jama.2024.15775.
3
Respiratory syncytial virus in infants: what's to know.
Minerva Pediatr. 2018 Dec;70(6):552. doi: 10.23736/S0026-4946.18.05437-3.
4
Respiratory syncytial virus: pervasive yet evasive.
CMAJ. 2004 Jan 20;170(2):191.
5
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
6
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
J Infect. 2019 May;78(5):382-392. doi: 10.1016/j.jinf.2019.02.003. Epub 2019 Feb 8.
7
Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.
Clin Infect Dis. 2017 Sep 15;65(6):1020-1025. doi: 10.1093/cid/cix432.
8
Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives.
Minerva Pediatr. 2018 Dec;70(6):566-578. doi: 10.23736/S0026-4946.18.05305-7. Epub 2018 Oct 18.
9
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020.
Clin Infect Dis. 2024 May 15;78(5):1352-1359. doi: 10.1093/cid/ciae085.
10
RSV vaccine use--the missing data.
Expert Rev Vaccines. 2016;15(2):149-52. doi: 10.1586/14760584.2016.1114419. Epub 2015 Dec 4.
引用本文的文献
1
Post-marketing safety monitoring of RSV vaccines: A real-world study based on the Vaccine Adverse Event Reporting System (VAERS).
Hum Vaccin Immunother. 2025 Dec;21(1):2550857. doi: 10.1080/21645515.2025.2550857. Epub 2025 Aug 27.
2
Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024.
Prev Med Rep. 2025 Jun 26;56:103150. doi: 10.1016/j.pmedr.2025.103150. eCollection 2025 Aug.
3
Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older.
JAMA Netw Open. 2025 May 1;8(5):e258322. doi: 10.1001/jamanetworkopen.2025.8322.
4
Recent advances in the prevention and treatment of respiratory syncytial virus disease.
J Gen Virol. 2025 Apr;106(4). doi: 10.1099/jgv.0.002095.
5
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia.
Lancet Reg Health West Pac. 2025 Feb 26;56:101506. doi: 10.1016/j.lanwpc.2025.101506. eCollection 2025 Mar.
6
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines.
Vaccines (Basel). 2025 Jan 21;13(2):97. doi: 10.3390/vaccines13020097.
7
Update on Vaccination Recommendations for Adults with HIV.
Curr HIV/AIDS Rep. 2025 Feb 20;22(1):17. doi: 10.1007/s11904-025-00731-6.
8
The recent landscape of RSV vaccine research.
Ther Adv Vaccines Immunother. 2025 Jan 10;13:25151355241310601. doi: 10.1177/25151355241310601. eCollection 2025.
9
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.
Vaccines (Basel). 2024 Nov 25;12(12):1317. doi: 10.3390/vaccines12121317.
10
Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study.
BMC Med. 2024 Oct 17;22(1):478. doi: 10.1186/s12916-024-03687-3.
本文引用的文献
1
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. doi: 10.15585/mmwr.mm7229a4.
2
Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845.
3
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis.
Open Forum Infect Dis. 2022 Jun 17;9(7):ofac300. doi: 10.1093/ofid/ofac300. eCollection 2022 Jul.
4
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
JAMA Netw Open. 2022 Apr 1;5(4):e228879. doi: 10.1001/jamanetworkopen.2022.8879.
5
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
6
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.
Vaccine. 2011 Jan 10;29(3):599-612. doi: 10.1016/j.vaccine.2010.06.003. Epub 2010 Jun 18.
Zotero 插件